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Current research is aiming to push the boundaries of the point at which a diagnosis of Alzheimer Disease (AD) can be made.
Clinical syndromes such as Mild Cognitive Impairment (MCI) and various clinical and biological markers of AD may help to
identify people in the early stage of AD, before a full dementia syndrome is present. In the ﬁrst part of this paper, we discuss
whether MCI represents incipient AD, and examine some of the methods currently used in research to identify AD patients in the
preclinical phase. In the second part, we discuss whether speciﬁc guidelines are needed for the diagnosis and management of MCI
and incipient AD, and consider the potential impact of this on clinical practice and public health from the perspective of patients,
caregivers, and healthcare providers.
1.Introduction:TheConceptofMCIand
IncipientAD
Currently, dementia of the Alzheimer type is diagnosed
clinically according to diagnostic criteria [1]. These criteria
include deﬁcits in memory and other cognitive functions,
and the symptoms have a gradual onset and progressive
deterioration. The H. Braak and E. Braak [2, 3] staging
describes an increasing burden of the neuropathological
hallmarksofAlzheimerdisease(AD),neuroﬁbrillarytangles,
and amyloid plaques, with increasing dementia severity,
mainly starting in the brain regions associated with memory
functioning such as the hippocampus and entorhinal cortex.
Evidence now clearly shows that the disease starts before
the symptoms of a full dementia syndrome are present. AD
related pathology, such as beta amyloid deposition, may
already begin occurring even ten to twenty years before a
clinicaldiagnosisofdementiacanbemade[4].Furthermore,
deﬁcitsincognitivefunctioningmaystarttoappearthree[5],
six, or even up to ten years [6] before a clinical diagnosis of
AD.
Several syndromes that identify patients at high
risk of developing dementia—or “preclinical, early AD”
syndromes—have been proposed, including Mild Cognitive
Impairment (MCI) and others; for a review see Mariani and
colleagues [7]. A decade ago, Petersen et al. [8] proposed
diagnostic criteria to describe patients who were neither
normal nor demented, but had a mild form of cognitive
impairment characterized by memory deﬁcits. The MCI
paradigm is based on the assumption that patients with
AD develop symptoms, particularly memory impairment,
gradually and, therefore, there may be an intermittent stage
between normal aging and dementia characterized primarily
by episodic memory deﬁcits. These MCI patients have a
high risk of progressing to a full dementia syndrome within
af e wy e a r s[ 8], although, as discussed later, the evolution is
heterogeneous.
In the last decade, much focus has been paid to
identifying clinically diagnosable syndromes of incipient
AD. Criteria for MCI, and other syndromes, have been
revised several times [9–11], with interest in identifying
speciﬁccharacteristicsofMCIpatientswhoareatthehighest
risk of progressing to AD. People with MCI progress to
dementia at a rate of about 6% to 15% per year [7, 8,
12, 13], although the condition is heterogeneous and some
MCI patients do not develop dementia. As discussed in2 International Journal of Alzheimer’s Disease
ar e c e n ts y s t e m a t i cr e v i e wo fM C I[ 7], a number of factors
h a v eb e e ns u g g e s t e dt of u r t h e rp r e d i c tc o n v e r s i o nt oA D
in MCI patients, and it is becoming increasingly evident
that biomarkers, such as cerebrospinal ﬂuid (CSF) markers
including beta-amyloid1−42 and total tau protein, may have a
goodaccuracyforidentifyingimpendingADinMCIpatients
[14] compared to healthy controls. Although the diﬀerential
diagnostic capacity of using CSF markers between the
preliminary states of various dementia disorders has not yet
been thoroughly studied, the discoveries regarding AD are
pushing the boundaries as to when AD can be identiﬁed and
diagnosed in individuals.
2. Guidelinesfor AD and Dementia
Guidelines for the diagnosis and management of AD and
other dementias are regularly published, updated, and
revised in the USA and elsewhere in the world [15–19].
The latest European recommendations for the diagnosis and
management of AD were published by the European Federa-
tion of Neurological Societies (EFNS) [17]. These evidence-
based guidelines were created through a consensus process
to provide guidance for physicians concerning diagnostic
evaluationandmanagementofdementia,includingpharma-
cological and nonpharmacological treatment, management
of behavioral and psychological symptoms of dementia
(BPSD), counseling and support for caregivers, and so forth.
The EFNS guidelines state that the recommendations are
relevantonlytodementia,anddonotincludeMCI.Recently,
Dubois et al. [20] published new diagnostic criteria for the
early detection of AD. These were proposed as research
criteria, rather than for clinical diagnosis and patient
management, and incorporate clinical evidence of episodic
memory loss (isolated or with other cognitive deﬁcits) with
biomarkers (CSF, neuroimaging, genetic) to identify patients
in an early, predementia stage of AD. The criteria are novel
because rather than focusing on the dementia syndrome
they focus on clinical, biological, structural, and biochemical
presence of AD in a predementia phase. These, and other,
criteria for syndromes of early preclinical phases of AD
raise controversial questions in the scientiﬁc and medical
world. Should physicians diagnose MCI or incipient AD?
Should MCI patients be treated? How should physicians and
healthcare workers manage the healthcare of patients with
MCI? Should dementia guidelines be revised to incorporate
MCI? In this paper, we will discuss the disadvantages
and advantages of omitting MCI and incipient AD from
dementia guidelines, and discuss the potential impact on
clinical practice and public health from the perspective of
patients, caregivers, and healthcare providers.
3.Does MCIRepresent IncipientAD?
Theﬁrstrelevantquestiontoaskinthisdiscussioniswhether
syndromes such as MCI truly represent an early preclinical
phase of AD. Research both from clinical- and population-
based samples suggest that MCI patients have a high risk
of progressing to a full dementia syndrome; a meta-analyses
[12]oflongitudinalstudiesofindividualswithMCIreported
an annual conversion rate of 8.1% in clinical settings, and
6.8% in community-based settings. Pooled-analysis [13]
suggests that about one third of MCI patients will convert
to AD, with a higher conversion rate in the ﬁrst few years
following MCI diagnosis. However, it has consistently been
shown that not all MCI patients will develop AD [7, 12], and
that cognitive impairment in the elderly has heterogeneous
risk factors [21] and potentially diverse etiologies and causes
[11]. Although neuropathological studies on MCI patients
indicate that pathological ﬁndings in the brain structures
involved in memory represent a transition between normal
aging and AD, many concurrent pathological abnormalities
are also present in these patients, including vascular lesions
and argyrophilic grain disease [22]. Further, neuropatho-
logical investigations in patients who progressed from MCI
to AD show a heterogeneous pathological outcome [23]. In
addition, not all AD patients pass through a clinically iden-
tiﬁable stage of MCI with subjective and objective memory
deﬁcits present prior to dementia diagnosis [24]. Thus, the
evidence suggests that, although MCI does represent a group
of individuals with a high risk of progressing to AD, MCI
doesnotequalincipientADbecausenotallMCIpatientswill
develop AD.
As mentioned previously, much work has been done to
further characterize MCI patients to identify which indi-
viduals are most likely to develop AD. Therefore, although
patients with a clinical diagnosis of MCI do not necessarily
have AD, there are subsets of MCI patients who have
a neurodegenerative AD etiology, and are in the early
phase of AD. Functional markers, cognitive testing, hip-
pocampal and entorhinal cortex atrophy, neuropsychiatric
disorders, genetic factors such as Apolipoprotein E (ApoE)
epsilon 4 (ε4) allele, increased age, low education, and
motor dysfunction are all markers that have been shown
to identify which MCI patients have the highest risk of
developing AD [7]. It is also evident that combining factors
(including neuroimaging, clinical, and sociodemographic
markers) [25, 26] increases the prediction for identifying
which MCI patients will progress to AD. Indeed, Dubois
and colleagues’ research criteria for the early detection of
AD [20] incorporate clinical evidence of cognitive deﬁcits
with neuroimaging, CSF, and genetic biomarkers. However,
it is not yet clear which markers and cutoﬀ values are the
best for identifying incipient AD patients; although Dubois
and colleagues make some suggestions for biomarkers,
such as hippocampal volume loss, it was emphasized that
research should identify and validate other biomarkers and
neuroimaging regions of interest in the future. It is worth
notingthatalthoughcombiningmarkerswillhelptoincrease
the positive predictive value for identifying which MCI
patients will develop AD, ultimately this may lead to a drop
in the other diagnostic values. Tests and markers with high
positive predictive value are likely to have lower sensitivity,
especiallyatthepopulationlevel.Therefore,veryfewpatients
with AD will be able to be identiﬁed in the early stage of the
disease.
As discussed elsewhere in this special issue, much
research eﬀort has been made in the ﬁeld of biomarkers,International Journal of Alzheimer’s Disease 3
particularly CSF, for identifying patients in the early, prede-
mentia, phase of AD. A multicenter study of the CSF markers
in MCI patients has shown innovative results concerning
the use of beta-amyloid1−42, total tau protein, and tau
phosphorylated at position threonine 181, which was found
to have a good accuracy for identifying impending AD in
MCI patients [14]. This was one of the ﬁrst studies to pool
the data from a large range of single center studies. It showed
that the positive predictive value of these CSF markers for
identifying incipient AD in MCI patients was 62%, with a
sensitivity of 83%. However, despite these promising results,
the ﬁndings should be viewed with caution. An editorial
by Petersen and Tojanowski [27] highlighted the clinical
variability of the MCI patients as well as the variability in
CSF measurements in the diﬀerent centers in Mattsson and
colleagues’ work. Further, they acknowledged that although
the sensitivity and speciﬁcity of the CSF markers were
adequate for screening, they did not have high enough
accuracy to be used as diagnostic tests, although they may be
useful for use in clinical trials [27]. Interestingly, the positive
predictive value showed that 62% of MCI patients developed
AD when a combination of the three CSF markers was used
[14] .H o w e v e r ,t h i sp o s i t i v ep r e d i c t i v ev a l u en e e d st ob e
comparedwithothermarkersandclinicalsyndromes.Before
taking into consideration other markers, the cumulative
conversionratefromMCItoADacrossstudiesis31.4%[13].
Furthermore, other studies have shown that this positive
predictive value can be increased by combining other, less
invasive, markers. For example, a prediction model using
ﬁve factors (functional and olfactory markers, cognitive
testing, and MRI measures of hippocampal volume and
entorhinal cortex volume) had a positive predictive value
of more than 80% for identifying incipient AD in MCI
patients [25].
There are important limitations to consider when exam-
ining clinical and laboratory markers in MCI patients. First,
laboratory samples are mainly taken from clinical patient
populations, which may not be representative of the general
population. Consequently, the sensitivity of a laboratory
measure evaluated in a clinical sample does not reﬂect the
level of sensitivity of the test if used at the population level.
Second, a study in the general population showed that half
of AD patients have no subjective complaints about their
memory performance up to one to three years before AD
diagnosis, and one ﬁfth show absolutely no cognitive deﬁcits
[24]. This highlights the heterogeneity of patients in the
preclinical phase of AD. It is likely that patients who seek
medicaladviceforcognitiveproblemsareatamoreadvanced
stage of cognitive impairment, closer to the diagnosis of AD,
which will aﬀect the accuracy of measurements of sensitivity
and predictive values in markers such as CSF values. Finally,
the multicenter study by Mattsson et al. [14] found that
the diagnostic validity of CSF markers had less accuracy
in the multicenter analysis than the accuracy reported in
single-center settings. This highlights the importance of
replicating positive results from single centers, which are
often conducted on small study populations, and the need
for more multicenter trials and meta-analyses to determine
the accuracy of biomarkers for identifying incipient AD.
4.Do We Need Guidelines for the Diagnosis and
Management of MCI?
MCI is a frequently occurring syndrome in the elderly.
A European longitudinal study [28] reported an incidence
rate per 1000 person years of between 11.4 for amnestic-
MCI and 33.8 for other types of cognitive impairment,
and prevalence data suggests that cognitive impairment
syndromes in younger nondemented elderly actually exceed
dementia prevalence [29]. Given that MCI is a frequent
syndrome in older people, and that individuals with MCI
have a high risk of progressing to AD [7, 12], this raises
the question of what should be done with such patients.
As mentioned earlier, guidelines for the management of
dementiaoftendonotincluderecommendationsforpatients
with MCI. However, many of the issues regarding both
diagnosis and management of dementia may also be relevant
to the large number of elderly persons suﬀering from MCI,
who may or may not be in the early stage of AD. Clinically,
MCI could be viewed, not as a disease or disorder per se, but
asariskfactorforAD.Riskfactorssuchasthisarecommonly
addressed in other areas of medicine. Many conditions have
been shown to predispose an individual to a higher risk of
developing another medical condition, such as hypertension
for stroke and myocardial infarction, dyslipidemia for stroke
and other vascular disease, diabetes for osteoporosis and so
forth. In good clinical practice, clinicians explain the risks
associated with such conditions with their patients, and plan
appropriate care and management. In this way, MCI should
be viewed as a clinical syndrome that has a high risk of
progressing to AD. Thus, if clinicians were to consider MCI,
not as incipient AD, but as a risk factor for developing AD,
certain issues concerning management and treatment that
have been raised for dementia, may be relevant also to MCI.
5. Treatment of MCI
First, although dementia disorders such as AD are currently
not curable, there are a number of symptomatic phar-
maceutical treatments that are recommended in guidelines
for dementia [17, 30]. Conversely, there are currently no
approved drugs for the treatment of MCI or early preclinical
AD. Clinical trials on MCI patients have had limited success;
none of the trials, including donepezil, rivastigmine, rofe-
coxib, galantamine, and vitamin E, have demonstrated con-
vincing eﬀects for delaying progression from MCI to AD [31,
32].However,othertrialsareongoing,anddataonsubsetsof
MCI patients have identiﬁed potentially promising avenues
for future research. For example, although randomized-
control trials on cholinesterase inhibitors such as donepezil
have shown little or no reduction in the risk of conversion
from MCI to AD [33–35], the results of one trial suggested
that MCI patients with depressive symptoms treated with
donepezilhadalowerriskofconversiontoAD[36].Without
the availability of eﬀective treatment strategies, and in the
absence of approved drugs for the treatment of MCI or
incipient AD, one may question the beneﬁts of diagnosing
such syndromes. Thus, dementia guidelines, such as those
proposed by EFNS, might be right to avoid discussing4 International Journal of Alzheimer’s Disease
disease-speciﬁc treatment strategies for MCI, since MCI per
se is not a disease, and currently there are no approved
drugsforMCI.However,pharmacologicaltreatmentsarenot
the only recommendations suggested in current guidelines
for dementia, and the other recommendations might be of
relevance to MCI patients as well as those with dementia,
including suggestions for diagnosis, management of BPSDs,
and support for families and caregivers.
6.Nonpharmacological Treatment and
Interventions
Although there are no currently approved pharmacological
treatments for MCI, nonpharmacological interventions have
also been the focus of recent research. Management of
risk factors and somatic disorders, lifestyle changes, and
cognitive intervention programmes may be beneﬁcial to
certain patients, and may be advantageous as they might
have less side eﬀects and risks than pharmacological drugs.
CognitiverehabilitationstudiesinMCI[37–39]haveshowed
improvement in ADL functioning, mood, and memory
following training, although there is no evidence for delayed
progression from MCI to AD. Further, if MCI patients
are told of their high risk of developing AD, there are
possibilities for modifying risk factors associated with AD,
such as diet, somatic, and lifestyle factors [40]. Further, as
it has been shown that MCI has heterogeneous risk factors
[21]andthatMCImayhavediversesomatic,psychiatric,and
neurological etiologies [11], the modiﬁcation of somatic and
lifestyle factorsmay be beneﬁcial to the overall healthof MCI
patients, even those who are not in a preclinical phase of AD.
7. Disclosure of MCI Diagnosis
There is ongoing debate as to whether a formal diagnosis
of MCI should be made and disclosed to patients in the
clinical setting. The fact is that increasing numbers of
elderly people are approaching physicians complaining of
memory problems, and there is a high incidence of both
MCI and other syndromes of cognitive impairment in the
elderly [28]. There may be some beneﬁts to disclosing a
diagnosis of MCI to a patient and discussing the associated
risk of developing AD. First, it allows patients to plan
for their future before their cognitive impairment becomes
severe, including ﬁnancial planning, and the planning of
care and living arrangements for the future. Second, in
some cases it may be helpful for individuals to have a
formal diagnosis that somewhat explains their symptoms.
From the physician’s perspective, giving an early diagnosis
may be beneﬁcial as the patient will have better cognitive
capacities to understand the diagnosis and discuss future
treatment and care options; indeed, studies have shown
that physicians are often reluctant to disclose a diagnosis
of dementia in more severe stages of the disease due to
lack of comprehension by the patient [41]. Furthermore,
physicians may be concerned that disclosing a diagnosis of
dementia may trigger catastrophic events in the patient such
as depression or suicide. However, a study by Carpenter et
al. [42] examined changes in depression and anxiety both
in patients and their relatives before and after the diagnosis
of dementia. They found that there were no changes in
depression status in either patients or their next-of-kin after
a disclosure of a dementia diagnosis, but levels of anxiety
decreased substantially after receiving the diagnosis. This
supports the idea that receiving a formal diagnosis that
explains the symptoms and memory loss can actually be
beneﬁcial to a patient.
Interesting lessons can also be learned from studies
investigating the eﬀect of disclosing genetic risk of AD to
individuals, such as ApoE ε4, a cardiovascular risk factor
which is also associated with an increased risk of developing
AD [43]. Both MCI and the ApoE ε4 genotype are associated
with a higher risk of AD but do not represent a deﬁnite
risk; that is, not all patients with MCI or ApoE ε4w i l l
develop AD. The REVAL study group [44] investigated the
eﬀect of disclosing AD risk (both ApoE genotype and a
numeric risk estimate) to family members of AD patients
using a randomized-control trial design. They found no
diﬀerences in short-term psychological symptoms such as
anxiety, depression, or distress between people who were
told that they had a genetic risk of developing AD (ApoE
ε4 carriers) than those who were not told their genotype.
However, when questioned after one year, individuals were
more likely to recall their genotype than their numerical
lifetime risk estimate of AD [45]. The authors suggested
that clinicians, therefore, needed to ﬁnd an appropriate
manner to communicate AD risk and probabilities. Most
interestingly, however, was that disclosure of genetic AD risk
was associated with a change in behaviors; a large proportion
of individuals made changes to their long-term healthcare
insurance after learning they were ApoE ε4 carriers [46]a n d
more than half made changes to their health behavior, such
as vitamin intake and exercise [47]. Although speciﬁc studies
on the disclosure of MCI diagnosis are needed, the results of
therestudiesondisclosinggeneticADrisksuggestpotentially
beneﬁcial eﬀects of informing an at-risk individual that they
have a high risk of developing AD.
8. Recommendations for
the Management of BPSD
AlthoughtherearenoapprovedtreatmentsforMCI,patients
with this syndrome might have other related symptoms
that can be treated. The EFNS guidelines for dementia
stipulate that physicians should be aware of the importance
of treating behavioral and psychiatric symptoms for the
potential beneﬁt of the patients and carers. This may also
be relevant to MCI patients. Studies both from clinical- and
population-based samples consistently report a high burden
of BPSD in MCI patients, particularly depression, anxiety,
and irritability (for a review see Monastero and colleagues
[48]).IndeedthepatternofBPSDinMCIaresimilartothose
observed in patients with dementia, and symptoms have
been observed in more than one third of patients, with many
studies reporting a higher prevalence [48], even up to 85%.
Nevertheless, the role of BPSD in MCI remains unclear and,International Journal of Alzheimer’s Disease 5
thus,treatmentofspeciﬁcsymptomsorpsychiatricdisorders
in this group of patients is controversial. A population-
based study showed that anxiety in MCI patients was
associated with an ongoing AD related neurodegeneration
[49], and clinical-based studies suggest a similar role for
apathy [50–52]. In contrast, depression in MCI is generally
not associated with progression to AD [49, 53]. There are
currently no clinical trials investigating the eﬀect of treating
BPSD and psychiatric disorders in MCI patients, and thus
it is not known whether pharmacological treatments are
eﬀective either in slowing the progression from MCI to AD
or in reducing the severity of neuropsychiatric symptoms in
these patients. Indeed, the situation is similar for patients
already in the stage of clinical dementia; current guidelines
for dementia [17] highlight these controversies.
9. Patient GuidelinesandAdvice
Guidelines on MCI for healthcare workers as well as patients
have already been published in America. In 2010, the
American Academy of Physician Assistants [54] published
guidelines for physician assistants, stating that they should
be able to recognize and treat MCI and dementia. Speciﬁc
suggestions were made for screening tools, cognitive and
somatic evaluation of at-risk patients, as well as tenta-
tive recommendations for treatment strategies. A Patient
Page, published in the Journal of the American Medical
Association [55], aims to provide patients and families
with general information about MCI, including possible
conditions associated with MCI, a description of diagnostic
techniques, and some recommendations for prevention,
mainly the management of high blood pressure and other
chronic conditions, as well as social activities and dietary
changes.ApatientandfamilyfactsheetonMCI,publishedin
The Neurologist [56] describes potential causes of cognitive
impairment in the elderly, rather than focusing speciﬁcally
onAD,anddescribesdiagnosticproceduresandexamination
that might be conducted on patient with suspected cognitive
problems. It also makes suggestions for life style changes,
including social and dietary changes.
10. Conclusions
In conclusion, MCI is not a disease or disorder, but a risk
factor for developing dementia and AD. Although studies
examining biological markers and other factors in MCI
patients have identiﬁed markers that further increase the
risk of developing AD in these patients, we are still not at
a stage where we can accurately identify with 100% accuracy
which patients are in the early phase of AD. Consequently,
current guidelines for the diagnosis and management of
AD and dementia often do not include speciﬁc suggestions
for MCI. Despite this, many of the recommendations made
for patients with dementia, may also be relevant to people
with MCI. Therefore, peer-reviewed, consensus guidelines
for the diagnosis and management of incipient AD or
MCI might be beneﬁcial in the future. However, it is
imperative to focus future research on identifying more
accurate diagnostic markers to deﬁne incipient AD, and to
study the eﬀect of informing patients that they have a high
risk of developing AD, in terms of psychological reactions
and potential beneﬁts for planning appropriate management
and prevention strategies in MCI patients.
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